Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
284.9 EUR | +1.35% | -3.46% | -14.98% |
04-30 | SARTORIUS : Target cut by -6.1% | |
04-24 | SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg | ZD |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 76.6 and 51.67 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.98% | 18.57B | - | ||
-42.23% | 2.82B | C+ | ||
+17.00% | 1.85B | - | - | |
-0.51% | 1.66B | - | ||
+27.75% | 1.23B | B+ | ||
-13.90% | 989M | - | ||
-21.76% | 896M | - | C- | |
-2.80% | 734M | - | ||
-24.00% | 667M | B+ | ||
+7.78% | 498M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- SRT3 Stock
- Ratings Sartorius AG